Features of binge eating disorder in obese or overweight individuals with stable bipolar disorder participating in a weight loss trial - a post hoc analysis.

IF 2.7 4区医学 Q2 PSYCHIATRY

International Journal of Psychiatry in Clinical Practice Pub Date : 2025-08-24 DOI:10.1080/13651501.2025.2549307

Anna I Guerdjikova, Thomas J Blom, Nicole Mori, Francisco Romo-Nava, Susan L McElroy

{"title":"Features of binge eating disorder in obese or overweight individuals with stable bipolar disorder participating in a weight loss trial - a post hoc analysis.","authors":"Anna I Guerdjikova, Thomas J Blom, Nicole Mori, Francisco Romo-Nava, Susan L McElroy","doi":"10.1080/13651501.2025.2549307","DOIUrl":null,"url":null,"abstract":"Objective: To inform clinical decision-making for patients with obesity, binge eating disorder (BED) and bipolar disorder (BD), we compared individuals with BED and those without BED who participated in a randomised controlled trial (RCT) of liraglutide for weight loss in stable BD with obesity.Methods: This was a post hoc analysis of a published, 40-week, placebo-controlled, double-blind trial of liraglutide in 60 participants with stable BD and obesity or overweight. Participants with BED were compared to those without BED regarding demographics, psychiatric and medical comorbidity, BD treatment, and response to liraglutide versus placebo.Results: Compared to those without BED (N = 43), participants with BED (N = 17) had a higher body mass index (BMI) and higher HbA1c levels, were taking more antidepressants, and had higher Binge Eating Scale (BES) scores and Three Factor Eating Questionnaire (TFEQ) disinhibition of eating and hunger subscale scores. Among the 17 BED participants, liraglutide (N = 9) and placebo (n = 8) were associated with similar reductions in percent change of body weight and BES scores. Liraglutide was well tolerated, but the BED group experienced significantly more nausea/vomiting (p = .04), constipation (p = .02) and anxiety (p = .02).Conclusions: RCTs are warranted to enrich the pharmacological armamentarium available to treat such complex patients.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":" ","pages":"1-4"},"PeriodicalIF":2.7000,"publicationDate":"2025-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Psychiatry in Clinical Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13651501.2025.2549307","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To inform clinical decision-making for patients with obesity, binge eating disorder (BED) and bipolar disorder (BD), we compared individuals with BED and those without BED who participated in a randomised controlled trial (RCT) of liraglutide for weight loss in stable BD with obesity.

Methods: This was a post hoc analysis of a published, 40-week, placebo-controlled, double-blind trial of liraglutide in 60 participants with stable BD and obesity or overweight. Participants with BED were compared to those without BED regarding demographics, psychiatric and medical comorbidity, BD treatment, and response to liraglutide versus placebo.

Results: Compared to those without BED (N = 43), participants with BED (N = 17) had a higher body mass index (BMI) and higher HbA1c levels, were taking more antidepressants, and had higher Binge Eating Scale (BES) scores and Three Factor Eating Questionnaire (TFEQ) disinhibition of eating and hunger subscale scores. Among the 17 BED participants, liraglutide (N = 9) and placebo (n = 8) were associated with similar reductions in percent change of body weight and BES scores. Liraglutide was well tolerated, but the BED group experienced significantly more nausea/vomiting (p = .04), constipation (p = .02) and anxiety (p = .02).

Conclusions: RCTs are warranted to enrich the pharmacological armamentarium available to treat such complex patients.

查看原文本刊更多论文

参与减肥试验的肥胖或超重稳定双相情感障碍患者暴食障碍的特征-事后分析。

目的：为了给肥胖、暴饮暴食症（BED）和双相情感障碍（BD）患者的临床决策提供依据，我们比较了参加利拉鲁肽用于稳定型BD合并肥胖患者减肥的随机对照试验（RCT）的BED患者和非BED患者。方法：这是一项已发表的、为期40周的、安慰剂对照的、利拉鲁肽双盲试验的事后分析，该试验对60名患有稳定双相障碍、肥胖或超重的参与者进行了研究。将BED患者与非BED患者在人口统计学、精神病学和医学合并症、BD治疗以及对利拉鲁肽和安慰剂的反应等方面进行比较。结果：与没有BED的参与者（N = 43）相比，BED的参与者（N = 17）有更高的身体质量指数（BMI）和更高的HbA1c水平，服用更多的抗抑郁药，并且有更高的暴食量表（BES）得分和三因素饮食问卷（TFEQ）进食和饥饿亚量表的去抑制得分。在17名BED参与者中，利拉鲁肽（N = 9）和安慰剂（N = 8）与体重变化百分比和BES评分相似的降低相关。利拉鲁肽耐受性良好，但BED组明显出现更多恶心/呕吐（p = 0.04）、便秘（p = 0.02）和焦虑（p = 0.02）。结论：随机对照试验有必要丰富可用于治疗此类复杂患者的药理学手段。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Psychiatry in Clinical Practice 医学-精神病学

CiteScore

6.00

自引率

3.30%

发文量

审稿时长

>12 weeks

期刊介绍： International Journal of Psychiatry in Clinical Practice provides an international forum for communication among health professionals with clinical, academic and research interests in psychiatry. The journal gives particular emphasis to papers that integrate the findings of academic research into realities of clinical practice. Focus on the practical aspects of managing and treating patients. Essential reading for the busy psychiatrist, trainee and interested physician. Includes original research papers, comprehensive review articles and short communications. Key words: Psychiatry, Neuropsychopharmacology, Mental health, Neuropsychiatry, Clinical Neurophysiology, Psychophysiology, Psychotherapy, Addiction, Schizophrenia, Depression, Bipolar Disorders and Anxiety.